Psoriasis research record
23 treatments have a posted result against a comparison group. The exact treatment and comparison numbers are below.
The guide helps with care decisions. This page is the supporting trial record.
01
These treatments have at least one completed trial that posted a result against a comparison group — the only kind of result that can show the treatment itself made the difference. Each card is one trial against its own comparator, so cards can’t be compared head-to-head. Every result-posting study in the record was scanned, not just recent ones. A “vehicle” is the same cream or gel without the active ingredient — the fairest comparison for a topical.
86 of 100
Ixekizumab 80mg every 2 weeks (n=176)
3 of 100
placebo (n=88)
83 more people per 100 reached clear or almost-clear skin at week 12.
Outcome: Percentage of Participants With a Static Physician Global Assessment (sPGA) Score of Clear (0) or Minimal (1) With at Least a 2 Point Improvement · NCT03364309 details · ClinicalTrials.gov record · Phase 3 · Industry-run
81 of 100
Bimekizumab 320 mg every 4 weeks (n=32)
0 of 100
placebo (n=15)
81.3 more people per 100 reached at least 90% less psoriasis severity at week 16.
Serious adverse events in this trial: 0 of 32 on treatment vs 1 of 15 in the comparison group (submitted counts).
Outcome: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16 · NCT05020249 details · ClinicalTrials.gov record · Phase 3 · Industry-run · published: Youn SW et al.
72 of 100
Certolizumab Pegol 400 mg (ITT) (n=58)
2 of 100
placebo (n=59)
70.7 more people per 100 reached clear or almost-clear skin at week 12.
Outcome: Achievement of a Physician's Global Assessment (PGA) of Clear or Almost Clear at Week 12 · NCT00245765 details · ClinicalTrials.gov record · Phase 2 · Industry-run · published: Reich K et al.
78 of 100
Adalimumab Eow (n=338)
12 of 100
placebo (n=87)
66.3 more people per 100 reached at least 75% less psoriasis severity at week 12.
Outcome: Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response at Week 12 · NCT01646073 details · ClinicalTrials.gov record · Phase 3 · Industry-run
69 of 100
140 mg Brodalumab (n=629)
6 of 100
placebo (n=315)
63.2 more people per 100 reached the trial’s improvement bar at 12 weeks.
Serious adverse events in this trial: 10 of 629 on treatment vs 3 of 315 in the comparison group (submitted counts).
Outcome: Percentage of Participants With Psoriasis Area Severity Index (PASI) 75 at Week 12 · NCT01708629 details · ClinicalTrials.gov record · Phase 3 · Industry-run
42 of 100
Rofumilast Cream 0.3% (n=255)
6 of 100
vehicle (no active) (n=132)
36.3 more people per 100 reached clear or almost-clear skin at baseline (day 1) and week 8.
Serious adverse events in this trial: 2 of 286 on treatment vs 1 of 153 in the comparison group (submitted counts).
Outcome: Number of Participants Achieving Success in Investigator Global Assessment (IGA) Scale Assessment of Disease Severity at Week 8 · NCT04211363 details · ClinicalTrials.gov record · Phase 3 · Industry-run
15 more treatments have a comparative result — marked in the full treatment list below.
Before paying more for a newer option, check whether it beat the alternative in its own trial. In these primary outcomes, it didn’t:
37 registered psoriasis studies posted numeric results that this index maps to a treatment. Each has its own page showing exactly what was submitted, group by group.
Most trials compare against a placebo or vehicle. These posted outcomes compared one active treatment with another — the comparison that actually answers “which one?”:
Regulatory status of the tracked treatments — whether the molecule studied in the trials above is available over the counter, as a generic, or brand-only. 6 of them have an OTC, generic, or biosimilar route.
| Treatment | Status | United States | Canada |
|---|---|---|---|
| calcipotriene (calcipotriol) (Dovonex, Sorilux)Calcipotriene (US name) and calcipotriol (international name) are the same vitamin D analog. | Generic prescription available | Generic calcipotriene cream, ointment, and solution are available by prescription; also sold in combination with betamethasone (Taclonex and generics). source | Known as calcipotriol in Canada (Dovonex and combinations); prescription-only. source |
| desoximetasone (Topicort)Generic desoximetasone products contain the same corticosteroid as the Topicort brand. | Generic prescription available | Prescription corticosteroid available as generic creams, ointments, gels, and sprays. source | Available by prescription in Canada (Topicort and others). source |
| methotrexate (Trexall, Otrexup, Rasuvo)Methotrexate for psoriasis is the same generic molecule used in rheumatology and oncology, at different doses. | Generic prescription available | Oral tablets and injectable forms are long-established prescription generics. source | Generic methotrexate tablets and injections are available by prescription in Canada. source |
| adalimumab (Humira, Amjevita, Hyrimoz)Biosimilar versions of adalimumab are approved, highly similar alternatives to Humira available in both markets. | Biosimilar available | Humira plus multiple FDA-approved biosimilars (e.g., Amjevita, Hyrimoz, Hadlima) have been marketed since 2023; biosimilars are approved alternatives, not generics. source | Humira and several Health Canada-approved adalimumab biosimilars are marketed in Canada. source |
| etanercept (Enbrel, Erelzi, Brenzys)Etanercept biosimilars are approved in both countries but are actually sold only in Canada; in the US, Enbrel remains the only available version until patent expiry. | Biosimilar available | Only Enbrel is sold in the US; FDA-approved biosimilars (Erelzi, Eticovo) cannot launch until Enbrel patents expire (around 2029). source | Etanercept biosimilars (Brenzys, Erelzi) are marketed in Canada alongside Enbrel. source |
| ustekinumab (Stelara, Wezlana, Selarsdi)Biosimilar versions of ustekinumab became available in the US in 2025 and are also approved in Canada. | Biosimilar available | Stelara plus multiple FDA-approved biosimilars (Wezlana, Selarsdi, Pyzchiva, Yesintek and others) launched during 2025; some are designated interchangeable. source | Health Canada-approved ustekinumab biosimilars are marketed alongside Stelara. source |
| apremilast (Otezla)Apremilast is a small-molecule tablet but currently has no marketed US generic. | Brand-only prescription | Otezla tablets are brand-only by prescription; no generic is currently marketed in the US. source | Otezla is available by prescription in Canada. source |
| crisaborole (Eucrisa)Unlike tacrolimus and pimecrolimus, crisaborole has no generic; all products are the Eucrisa brand. | Brand-only prescription | Eucrisa 2% ointment is prescription-only; no generic is available. source | Eucrisa has been available in Canada since 2018; prescription-only, no generic. source |
| deucravacitinib (Sotyktu)Deucravacitinib is available only as the brand Sotyktu. | Brand-only prescription | Sotyktu tablets (approved 2022) are prescription-only; no generic. source | Sotyktu is marketed in Canada by prescription. source |
| roflumilast (Zoryve, Daliresp)The brand-only psoriasis cream and the generic COPD tablet contain the same molecule in different strengths and routes. | Brand-only prescription | Topical roflumilast (Zoryve cream and foam) is brand-only by prescription; oral roflumilast (Daliresp), approved for COPD, is generic. source | Zoryve cream (2023) and foam are approved by Health Canada; prescription-only. source |
| ruxolitinib (Opzelura, Jakafi, Jakavi)The same molecule is sold as the Opzelura skin cream and as oral tablets (Jakafi in the US, Jakavi in Canada) for different diseases. | Brand-only prescription | Opzelura 1.5% cream is prescription-only and brand-only; the same molecule is sold as oral tablets (Jakafi) for blood disorders. source | Opzelura cream authorized by Health Canada in October 2024 for atopic dermatitis and vitiligo; prescription-only. source |
| tapinarof (Vtama, Nduvra)Vtama (US) and Nduvra (Canada) contain the same tapinarof molecule under different brand names. | Brand-only prescription | Vtama 1% cream (psoriasis 2022, atopic dermatitis 2024) is brand-only by prescription. source | Approved by Health Canada in April 2025 under the brand Nduvra for plaque psoriasis; prescription-only. source |
| bimekizumab (Bimzelx)Bimekizumab is available only as the brand Bimzelx. | Biologic — brand only | Bimzelx (approved 2023) is a prescription biologic; no biosimilar. source | Bimzelx is marketed in Canada by prescription (approved 2022). source |
| brodalumab (Siliq)Brodalumab is available only as the brand Siliq in North America. | Biologic — brand only | Siliq is a prescription biologic dispensed under a REMS safety program; no biosimilar. source | Marketed as Siliq in Canada by prescription. source |
| certolizumab pegol (Cimzia)Certolizumab pegol is available only as the brand Cimzia. | Biologic — brand only | Cimzia injection is a prescription biologic; no biosimilar. source | Cimzia is marketed in Canada by prescription. source |
| guselkumab (Tremfya)Guselkumab is available only as the brand Tremfya. | Biologic — brand only | Tremfya is a prescription biologic; no biosimilar. source | Tremfya is marketed in Canada by prescription. source |
| ixekizumab (Taltz)Ixekizumab is available only as the brand Taltz. | Biologic — brand only | Taltz is a prescription biologic; no biosimilar. source | Taltz is marketed in Canada by prescription. source |
| risankizumab (Skyrizi)Risankizumab is available only as the brand Skyrizi. | Biologic — brand only | Skyrizi is a prescription biologic; no biosimilar. source | Skyrizi is marketed in Canada by prescription. source |
| secukinumab (Cosentyx)Secukinumab is available only as the brand Cosentyx in North America. | Biologic — brand only | Cosentyx is a prescription biologic; no biosimilar is marketed in the US. source | Cosentyx is marketed in Canada by prescription. source |
| tildrakizumab (Ilumya)Tildrakizumab is available only as the brand Ilumya in North America. | Biologic — brand only | Ilumya is a prescription biologic; no biosimilar. source | Marketed as Ilumya in Canada by prescription. source |
| gsk2982772GSK2982772 never advanced beyond clinical trials and is not available anywhere. | Investigational — not approved | Investigational RIPK1 inhibitor; psoriasis trials did not meet efficacy goals and development was discontinued; never approved. source | not verified |
| piclidenosonCF101 is the development code for piclidenoson, which remains investigational worldwide. | Investigational — not approved | Investigational oral A3 adenosine receptor agonist (piclidenoson) in phase 3 psoriasis trials; not approved in any market. source | not verified |
Regulatory status only, verified 2026-08-20 with one source per claim — not pricing, coverage, or a recommendation. Status can change; check the linked source.
Search by brand or generic name, or browse the 60 most-studied terms. They are ordered by what the public record can show, not by benefit or safety.
At Week 12, 66.5% of people in the Secukinumab 300mg (2 x 150 mg) group had the submitted improvement result (Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 12), compared with 48% in the Ustekinumab 2 x 45mg or 90mg group—18.5 more people per 100.
One submitted registry outcome, not a pooled estimate — from NCT02826603 details · ClinicalTrials.gov record · Phase 3 · Industry lead sponsor · vs another active treatment · earliest favourable time point: week 12
At 12-weeks, 62.3% of people in the Enbrel (Etanercept) group had the submitted improvement result (Proportion of Subjects Achieving PASI-75(75% Improvement in Psoriasis Area and Severity Index) From Baseline at Week 12), compared with 64.5% in the CHS-0214 group—2.2 fewer people per 100.
One submitted registry outcome, not a pooled estimate — from NCT02134210 details · ClinicalTrials.gov record · Phase 3 · Industry lead sponsor · vs another active treatment
At Week 12, 77.8% of people in the Adalimumab Eow group had the submitted improvement result (Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response at Week 12), compared with 11.5% in the Placebo group—66.3 more people per 100.
One submitted registry outcome, not a pooled estimate — from NCT01646073 details · ClinicalTrials.gov record · Phase 3 · Industry lead sponsor · vs placebo/vehicle · earliest favourable time point: week 12
At 12 Weeks, 21.7% of people in the Ustekinumab group had the submitted improvement result (Percentage of Participants With Psoriasis Area Severity Index (PASI) 100 at Week 12), compared with 0.6% in the Placebo group—21.1 more people per 100.
One submitted registry outcome, not a pooled estimate — from NCT01708603 details · ClinicalTrials.gov record · Phase 3 · Industry lead sponsor · vs placebo/vehicle · earliest favourable time point: week 12
At Baseline and week 16, 73.3% of people in the Apremilast 30 mg group had the submitted improvement result (Percentage of Participants Who Achieved a ≥ 4-point Reduction From Baseline in Dermatology Life Quality Index (DLQI) at Week 16), compared with 41.3% in the Placebo group—32 more people per 100.
One submitted registry outcome, not a pooled estimate — from NCT03774875 details · ClinicalTrials.gov record · Phase 4 · Industry lead sponsor · vs placebo/vehicle · earliest favourable time point: week 16
At Week 12, 86.4% of people in the Ixekizumab 80mg Q2W group had the submitted improvement result (Percentage of Participants With a Static Physician Global Assessment (sPGA) Score of Clear (0) or Minimal (1) With at Least a 2 Point Improvement), compared with 3.4% in the Placebo group—83 more people per 100.
One submitted registry outcome, not a pooled estimate — from NCT03364309 details · ClinicalTrials.gov record · Phase 3 · Industry lead sponsor · vs placebo/vehicle · earliest favourable time point: week 12
At 10 weeks, 80% of people in the Calcipotriene 80% group had the submitted improvement result (Physician Global Assessement), compared with 68% in the Vehicle 68% group—12 more people per 100.
One submitted registry outcome, not a pooled estimate — from NCT01745133 details · ClinicalTrials.gov record · Phase 4 · Other organization lead sponsor · vs placebo/vehicle · earliest favourable time point: week 10
At Week 16, 81.3% of people in the Bimekizumab 320 mg Q4W group had the submitted improvement result (Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16), compared with 0% in the Placebo group—81.3 more people per 100.
One submitted registry outcome, not a pooled estimate — from NCT05020249 details · ClinicalTrials.gov record · Phase 3 · Industry lead sponsor · vs placebo/vehicle · earliest favourable time point: week 16
At Week 12, 62.5% of people in the Tofacitinib 10 mg BID group had the submitted improvement result (Percentage of Participants Achieving a 75% Reduction in the Psoriasis Area and Severity Index (PASI75) at Week 12), compared with 33.3% in the Placebo group—29.2 more people per 100.
One submitted registry outcome, not a pooled estimate — from NCT01710046 details · ClinicalTrials.gov record · Phase 2 · Industry lead sponsor · vs placebo/vehicle · earliest favourable time point: week 12
At Week 16, 35.5% of people in the Deucravacitinib group had the submitted improvement result (Percentage of Participants With a Static Physician's Global Assessment (s-PGA) Score of 0 (Clear) or 1 (Almost Clear) With at Least a 2-point Reduction From Baseline at Week 16), compared with 8.2% in the Placebo group—27.3 more people per 100.
One submitted registry outcome, not a pooled estimate — from NCT05701995 details · ClinicalTrials.gov record · Phase 4 · Industry lead sponsor · vs placebo/vehicle · earliest favourable time point: week 16
At Week 12, 72.4% of people in the Certolizumab Pegol 400 mg (ITT) group had the submitted improvement result (Achievement of a Physician's Global Assessment (PGA) of Clear or Almost Clear at Week 12), compared with 1.7% in the Placebo (ITT) group—70.7 more people per 100.
One submitted registry outcome, not a pooled estimate — from NCT00245765 details · ClinicalTrials.gov record · Phase 2 · Industry lead sponsor · vs placebo/vehicle · earliest favourable time point: week 12
At Week 28, 25.5% of people in the Tildrakizumab 100 mg group had the submitted improvement result (The Proportion of Subjects Who Achieve at Least a 75% Improvement From Baseline in Total mNAPSI at Week 28), compared with 4.2% in the Placebo group—21.3 more people per 100.
One submitted registry outcome, not a pooled estimate — from NCT03897075 details · ClinicalTrials.gov record · Phase 3 · Industry lead sponsor · vs placebo/vehicle · earliest favourable time point: week 28
At Baseline to Week 12, 40.2% of people in the Tapinarof (DMVT-505) Cream Group group had the submitted improvement result (Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation), compared with 6.3% in the Vehicle Cream Group group—33.9 more people per 100.
One submitted registry outcome, not a pooled estimate — from NCT03983980 details · ClinicalTrials.gov record · Phase 3 · Industry lead sponsor · vs placebo/vehicle · earliest favourable time point: week 12
At Baseline (Day 1) and Week 8, 42.4% of people in the Rofumilast Cream 0.3% group had the submitted improvement result (Number of Participants Achieving Success in Investigator Global Assessment (IGA) Scale Assessment of Disease Severity at Week 8), compared with 6.1% in the Vehicle Cream group—36.3 more people per 100.
One submitted registry outcome, not a pooled estimate — from NCT04211363 details · ClinicalTrials.gov record · Phase 3 · Industry lead sponsor · vs placebo/vehicle
At 28 days, 30.5% of people in the Desoximetasone Spray 0.25% group had the submitted improvement result (Clinical Success), compared with 5% in the Placebo group—25.5 more people per 100.
One submitted registry outcome, not a pooled estimate — from NCT01206387 details · ClinicalTrials.gov record · Phase 3 · Industry lead sponsor · vs placebo/vehicle · earliest favourable time point: week 4
At 12 weeks, 69.2% of people in the 140 mg Brodalumab group had the submitted improvement result (Percentage of Participants With Psoriasis Area Severity Index (PASI) 75 at Week 12), compared with 6% in the Placebo group—63.2 more people per 100.
One submitted registry outcome, not a pooled estimate — from NCT01708629 details · ClinicalTrials.gov record · Phase 3 · Industry lead sponsor · vs placebo/vehicle · earliest favourable time point: week 12
At Week 16, 22.4% of people in the Alefacept Alone group had the submitted improvement result (Percentage of Subjects Who Achieve Psoriasis Area and Severity Index (PASI) 75 at Week 16), compared with 44.9% in the Alefacept + nbUVB group—22.5 fewer people per 100.
One submitted registry outcome, not a pooled estimate — from NCT00658606 details · ClinicalTrials.gov record · Phase 4 · Industry lead sponsor · dose comparison
At Week 12, 63.2% of people in the Reference group had the submitted improvement result (Treatment Success Assessed by IGA), compared with 56% in the Placebo group—7.2 more people per 100.
One submitted registry outcome, not a pooled estimate — from NCT02886702 details · ClinicalTrials.gov record · Phase 3 · Industry lead sponsor · vs placebo/vehicle · earliest favourable time point: week 12
At Week 16, 29.4% of people in the Induction: 30 mg Mirikizumab group had the submitted improvement result (Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)), compared with 0% in the Induction: Placebo group—29.4 more people per 100.
One submitted registry outcome, not a pooled estimate — from NCT02899988 details · ClinicalTrials.gov record · Phase 2 · Industry lead sponsor · vs placebo/vehicle · earliest favourable time point: week 16
At From Baseline (Day 1) to Day 84, Absolute Change From Baseline in Total Lesion Score for All Treatable Psoriatic Lesions to Day 84 changed by -2.2 score on a scale in the Ruxolitinib Phosphate 0.5% Cream group and -1.1 score on a scale in the Vehicle Cream group—a difference 1.1 score on a scale numerically larger in the selected group.
One submitted registry outcome, not a pooled estimate — from NCT00778700 details · ClinicalTrials.gov record · Phase 2 · Industry lead sponsor · vs placebo/vehicle
At 12 weeks, 8.5% of people in the CF101 2 mg group had the submitted improvement result (Number of Subjects Achieving Psoriasis Area and Severity Index (PASI) 75 at 12 Weeks), compared with 6.9% in the Placebo group—1.6 more people per 100.
One submitted registry outcome, not a pooled estimate — from NCT01265667 details · ClinicalTrials.gov record · Phase 2 / Phase 3 · Industry lead sponsor · vs placebo/vehicle · earliest favourable time point: week 12
At Baseline and Week 12, 5% of people in the GSK2982772 960 mg group had the submitted improvement result (Percentage (%) of Participants Who Achieved Greater Than or Equal (>=) to 75% Improvement From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 12), compared with 0% in the Placebo group—5 more people per 100.
One submitted registry outcome, not a pooled estimate — from NCT04316585 details · ClinicalTrials.gov record · Phase 1 · Industry lead sponsor · vs placebo/vehicle · earliest favourable time point: week 12
At Baseline (Day 1 pre-dose), Week 4, Change From Baseline in PASI Scores at Week 4 by Induction Dose changed by -13.2 units on a scale in the PF-06700841 60 mg QD as the Induction Dose group and -4.2 units on a scale in the Placebo as the Induction Dose group—a difference 9 units on a scale numerically larger in the selected group.
One submitted registry outcome, not a pooled estimate — from NCT02969018 details · ClinicalTrials.gov record · Phase 2 · Industry lead sponsor · vs placebo/vehicle
02
Only 9 of 528 result-posting psoriasis studies reported participants’ separately measured skin type. The public record therefore rarely shows whether people with skin like yours were included.
Among 528 completed studies with posted results, this is how often each participant detail was reported.
03
Open the part you need. Every count remains tied to this condition and snapshot.
596 completed trials did not post numeric results to the registry as of 2026-09-11. A missing result does not mean the treatment failed; it means the public cannot check what happened.
Among studies that ended at least 12 months ago, 523 of 1,054 (49.6%) posted results.
67% were led by industry, usually the company selling the treatment. This is context about who asked the question, not proof that a result is wrong.
Lead sponsor class is not the same as all funding, and it is not a study-quality score.
Across 567 primary-outcome time points, the typical trial judged success around week 12. This record does not support a claim of visible results in days.
Median study duration: 17 months.
| Year | Study starts |
|---|---|
| 1995 | 3 |
| 1997 | 3 |
| 1998 | 1 |
| 1999 | 2 |
| 2000 | 8 |
| 2001 | 6 |
| 2002 | 6 |
| 2003 | 21 |
| 2004 | 22 |
| 2005 | 34 |
| 2006 | 31 |
| 2007 | 54 |
| 2008 | 60 |
| 2009 | 48 |
| 2010 | 71 |
| 2011 | 49 |
| 2012 | 64 |
| 2013 | 76 |
| 2014 | 69 |
| 2015 | 75 |
| 2016 | 97 |
| 2017 | 82 |
| 2018 | 96 |
| 2019 | 88 |
| 2020 | 61 |
| 2021 | 82 |
| 2022 | 82 |
| 2023 | 73 |
| 2024 | 66 |
| 2025 | 81 |
| 2026 | 58 |
Study locations are not participant nationality or ancestry.
ClinicalTrials.gov data through · methodology v2.1.0 · snapshot 9a17314144e5…
Source: official ClinicalTrials.gov search · snapshot · result-mapping layer (v1.1.0, 2026-08-21) · field guide and citation.
As of 2026-09-11, 528 of 1,124 completed psoriasis trials registered on ClinicalTrials.gov have posted results, and 23 treatments have a posted result against a comparison group (Skinlogie Evidence Index, https://skinlogie.com/evidence-index/psoriasis).
Skinlogie’s derived figures are licensed CC BY 4.0 — reuse them with this attribution. Source records: ClinicalTrials.gov. Full dataset and citation format →